Medications and therapeutic apheresis procedures: Are we doing our best?

Journal of Clinical Apheresis

Volumn 28, Issue 1, 2013, Pages 73-77

  Ibrahim, Rami B ^a,b   Balogun, Rasheed Abiodun ^c  

^a MICHIGAN STATE UNIVERSITY   (United States)

^b WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF VIRGINIA HEALTH SYSTEM   (United States)

Author keywords

apheresis; drugs; plasmapheresis; removal; therapeutic plasma exchange; TPE

Indexed keywords

BASILIXIMAB; CEFEPIME; CEFTAZIDIME; CEFTRIAXONE; RITUXIMAB; VANCOMYCIN;

CONFERENCE PAPER; HUMAN; PLASMAPHERESIS; THERAPEUTIC PLASMA EXCHANGE;

ANTIBODIES, MONOCLONAL; BIOLOGICAL AVAILABILITY; BLOOD COMPONENT REMOVAL; BLOOD PROTEINS; BLOOD VOLUME; DIFFUSION; DRUG ADMINISTRATION SCHEDULE; FORECASTING; HALF-LIFE; HUMANS; OSMOLAR CONCENTRATION; PHARMACEUTICAL PREPARATIONS; PHARMACOKINETICS; PLASMA EXCHANGE; PROTEIN BINDING; SOLUTIONS;

EID: 84874042123     PISSN: 07332459     EISSN: 10981101     Source Type: Journal    
DOI: 10.1002/jca.21261     Document Type: Conference Paper

References (45)

1. Ibrahim RB, Balogun RA,. Medications in patients treated with therapeutic plasma exchange: prescription dosage, timing, and drug overdose. Semin Dial 2012; 25: 176-189.
2. Ibrahim RB, Liu C, Cronin SM, Murphy BC, Cha R, Swerdlow P, Edwards DJ,. Drug removal by plasmapheresis: an evidence-based review. Pharmacotherapy 2007; 27: 1529-1549.
3. Ibrahim RB, Liu CY, Cronin SM, Murphy BC, Cha R, Swerdlow P, Avila T, Smith ST, Lewis RA, Edwards DJ,. Influence of plasma exchange on the disposition of the fourth generation cephalosporin cefepime. J Oncol Pharm Pract 2009; 15: 217-222.
4. Fauvelle F, Lortholary O, Tod M, Guillevin L, Lochahi M, Leon A, Petitjean O,. Pharmacokinetics of ceftriaxone during plasma exchange in polyarteritis nodosa patients. Antimicrob Agents Chemother 1994; 38: 1519-1522.
5. Bozkurt F, Schollmeyer P, Keller E,. Kinetics of ceftazidime during plasmapheresis. Eur J Clin Pharmacol 1987; 33: 197-201.
6. McClellan SD, Whitaker CH, Friedberg RC,. Removal of vancomycin during plasmapheresis. Ann Pharmacother 1997; 31: 1132-1136.
7. Kliegman RM, Bertino JS Jr., Fanaroff AA, Gavan TL, Speck WT,. Pharmacokinetics of gentamicin during exchange transfusions in neonates. J Pediatr 1980; 96: 927-930.
8. Bertino JS Jr., Kliegman RM, Myers CM, Blumer JL,. Alterations in gentamicin pharmacokinetics during neonatal exchange transfusion. Dev Pharmacol Ther 1982; 4: 205-215.
9. Binimelis J, Bassas L, Marruecos L, Rodriguez J, Domingo ML, Madoz P, Armengol S, Magues MA, de Leiva A,. Massive thyroxine intoxication: evaluation of plasma extraction. Intensive Care Med 1987; 13: 33-38.
10. Alet P, Lortholary O, Fauvelle F, Tod M, Genereau T, Louchahi M, Leon A, Guillevin L, Petitjean O,. Pharmacokinetics of teicoplanin during plasma exchange. Clin Microbiol Infect 1999; 5: 213-218.
11. White RL, Garnett WR, Poynor WJ, Allen JH, Sharp DE,. Salicylate removal during plasma exchange in normal volunteers. Clin Pharm 1984; 3: 396-402.
12. Keller F, Hauff A, Schultze G, Offermann G, Reeck S, Molzahn M, Kreutz G, Vohringer F,. Effect of repeated plasma exchange on steady state kinetics of digoxin and digitoxin. Arzneimittelforschung 1984; 34: 83-86.
13. Balogun RA, Sahadevan M, Sevigny J, Kaplan AA,. Impact of therapeutic plasma exchange on cyclosporine kinetics during membrane-based lipid apheresis. Am J Kidney Dis 2001; 37: 1286-1289.
14. Varl J, Ponikvar R, Drinovec J, Kveder R, Zemva Z,. Effect of plasmapheresis on blood and plasma cyclosporin levels. Prog Clin Biol Res 1990; 337: 363-365.
15. Hale GA, Reece DE, Munn RK, Kniska AB, Phillips GL,. Blood tacrolimus concentrations in bone marrow transplant patients undergoing plasmapheresis. Bone Marrow Transplant 2000; 25: 449-451.
16. Przepiorka D, Suzuki J, Ippoliti C, Hester JP, Fritsche HA,. Blood tacrolimus concentration unchanged by plasmapheresis. Am J Hosp Pharm 1994; 51: 1708.
17. McDonald V, Manns K, Mackie IJ, Machin SJ, Scully MA,. Rituximab pharmacokinetics during the management of acute idiopathic thrombotic thrombocytopenic purpura. J Thromb Haemost 2010; 8: 1201-1208.
18. Darabi K, Berg AH,. Rituximab can be combined with daily plasma exchange to achieve effective B-cell depletion and clinical improvement in acute autoimmune TTP. Am J Clin Pathol 2006; 125: 592-597.
19. Khatri BO, Man S, Giovannoni G, Koo AP, Lee JC, Tucky B, Lynn F, Jurgensen S, Woodworth J, Goelz S, Duda PW, Panzara MA, Ransohoff RM, Fox RJ,. Effect of plasma exchange in accelerating natalizumab clearance and restoring leukocyte function. Neurology 2009; 72: 402-409.
20. Kuhle J, Gosert R, Buhler R, Derfuss T, Sutter R, Yaldizli O, Radue EW, Ryschkewitsch C, Major EO, Kappos L, Frank S, Hirsch HH,. Management and outcome of CSF-JC virus PCR-negative PML in a natalizumab-treated patient with MS. Neurology 2011; 77: 2010-2016.
21. Schwab N, Hohn KG, Schneider-Hohendorf T, Metz l, Stenner MP, Jilek S, DuPasquier RA, Gold R, Meuth SG, Ransohoff RM, Bruck W, Wiendl H,. Immunological and clinical consequences of treating a patient with natalizumab. Mult Scler 2012; 18: 335-344.
22. Schroder A, Lee DH, Hellwig K, Lukas C, Linker RA, Gold R,. Successful management of natalizumab-associated progressive multifocal leukoencephalopathy and immune reconstitution syndrome in a patient with multiple sclerosis. Arch Neurol 2010; 67: 1391-1394.
23. Damasceno A, von Glehn F, Martinez AR, Longhini AL, Deus-Silva L, Brandao CO, Santos LM, Damasceno BP,. Early onset of natalizumab-related progressive multifocal leukoencephalopathy. Mult Scler 2011; 17: 1397-1398.
24. Tan IL, McArthur JC, Clifford DB, Major EO, Nath A,. Immune reconstitution inflammatory syndrome in natalizumab-associated PML. Neurology 2011; 77: 1061-1067.
25. Papeix C, Depaz R, Tourbah A, Stankoff B, Lubetzki C,. Dramatic worsening following plasma exchange in severe post-natalizumab withdrawal multiple sclerosis relapse. Mult Scler 2011; 17: 1520-1522.
26. Ryschkewitsch CF, Jensen PN, Monaco MC, Major EO,. JC virus persistence following progressive multifocal leukoencephalopathy in multiple sclerosis patients treated with natalizumab. Ann Neurol 2010; 68: 384-391.
27. Diamond TH, Rajagopal R, Ganda K, Manoharan A, Luk A,. Plasmapheresis as a potential treatment option for amiodarone-induced thyrotoxicosis. Intern Med J 2004; 34: 369-370; author reply 70-71.
28. Scully M, McDonald V, Cavenagh J, Hunt BJ, Longair l, Cohen H, Machin SJ,. A phase 2 study of the safety and efficacy of rituximab with plasma exchange in acute acquired thrombotic thrombocytopenic purpura. Blood 2011; 118: 1746-1753.
29. Sabloff M, Wells PS,. The effect of plasmapheresis on the serum activity level of dalteparin: a case report. Blood Coagul Fibrinolysis 2000; 11: 395-400.
30. Sirvent AE, Borras-Blasco J, Enriquez R, Navarro-Ruiz A, Amoros FA,. Extracorporeal removal of vancomycin by plasmapheresis. Ann Pharmacother 2006; 40: 2279-2280.
31. Foral MA, Heineman SM,. Vancomycin removal during a plasma exchange transfusion. Ann Pharmacother 2001; 35: 1400-1402.
32. Osman BA, Lew SQ,. Vancomycin removal by plasmapheresis. Pharmacol Toxicol 1997; 81: 245-246.
33. Brophy DF, Mueller BA,. Vancomycin removal by plasmapheresis. Ann Pharmacother 1996; 30: 1038.
34. Martin SG, Kearns GL, Brod M, Austin G, Vaughan BC,. Impact of plasmapheresis on disopyramide elimination. Pediatr Nephrol 1999; 13: 323-325.
35. Prince ASKR, Phaneuf D, Neu HC,. The effect of exchange transfusion on the blood levels of ampicillin and gentamicin in neonates. Infection 1981; 9: 2-6.
36. Kale-Pradhan PB, Dehoorne-Smith ML, Jaworski DA, Hare BL, Provenzano R, Higgins MJ,. Evaluation of plasmapheresis on the removal of tobramycin. Pharmacotherapy 1995; 15: 673-676.
37. Ouellette SM, Visconti JA, Kennedy MS,. A pharmacokinetic evaluation of the effect of plasma exchange on tobramycin disposition. Clin Exp Dial Apheresis 1983; 7: 225-233.
38. Olsen KM, Marx MA, Monaghan MS, Barnes E, Ackerman BH, Pappas AA,. Phenytoin and plasmapheresis: importance of sampling times and impact of obesity. Ther Drug Monit 1994; 16: 624-628.
39. Kale PB, Thomson PA, Provenzano R, Higgins MJ,. Evaluation of plasmapheresis in the treatment of an acute overdose of carbamazepine. Ann Pharmacother 1993; 27: 866-870.
40. Sketris IS, Parker WA, Jones JV,. Plasmapheresis: its effect on toxic agents and drugs. Plasma Ther Transfus Technol 1984; 5: 305-317.
41. Kwon SU, Lim SH, Rhee I, Kim SW, Kim JK, Kim DW, Jeon ES,. Successful whole blood exchange by apheresis in a patient with acute cyclosporine intoxication without long-term sequelae. J Heart Lung Transplant 2006; 25: 483-485.
42. Leitner GC, Hiesmayr M, Hoecker P, Jilma B,. Therapeutic approaches in the management of oral cyclosporine A intoxication. Transplantation 2003; 75: 1764-1765.
43. Moorman MT, Epstein RB, Smith JW, O'Neal C, Holter JL,. Management of cyclosporine overdose in a hematopoietic stem cell transplant patient with sequential plasma exchange and red blood cell exchange. J Clin Apher 2011; 26: 156-158.
44. Hastings D, Patel B, Torloni AS, Mookadam F, Betcher J, Moss A, Heilman R, Mazur M, Hamawl K, Mulligan D, Reddy K, Mekeel K, Chakkera H,. Plasmapheresis therapy for rare but potentially fatal reaction to rituximab. J Clin Apher 2009; 24: 28-31.
45. Kaatz S, Kouides PA, Garcia DA, Spyropolous AC, Crowther M, Douketis JD, Chan AK, James A, Moll S, Ortel TL, Van Cott EM, Ansell J,. Guidance on the emergent reversal of oral thrombin and factor Xa inhibitors. Am J Hematol 2012; 87 (Suppl 1): S141-S145.